EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseOpen Access · CC BY 4.0

A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF

Renzo Laborante, Emiliano Bianchini, Benedikt N Beer, Valeria Valente iD, Dimitris Mavridis, Rossella Di Bidino, Domenico D'Amario, Kit Roes, Peter Mol, Christian Basile, Carin Corovic Cabrera iD, Raffaele Scorza iD und 4 weitere

European Journal of Heart Failure · 2026

DOI: 10.1093/ejhf/xuag233 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift European Journal of Heart Failure, 2026. Verfasst von Renzo Laborante und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, 118 83 Stockholm, Sweden. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Europe program, EUROPA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To assess the cost-effectiveness of guideline-directed medical treatments for heart failure with reduced ejection fraction (HFrEF) by performing a network meta-analysis (NMA) of randomized controlled trials (RCTs) feeding a subsequent cost-effectiveness analysis.

Methods

A random-effects NMA of RCTs was conducted. The primary analysis included only RCTs evaluating drugs in clinical settings as recommended in the 2021 European Society of Cardiology HF guidelines. Main efficacy outcomes included all-cause mortality (ACM) and total HF hospitalizations (HFH). A decision tree-Markov model was populated with NMA-derived efficacy estimates, quality-of-life data, and costs from United Kingdom (UK, main analysis), as well as Sweden and United States (US) (scenario analyses) healthcare perspectives.

Results

A total of 47 RCTs (75 978 patients) were included. The risk of ACM and total HFH decreased with increasing number of pharmacological treatments. In the main (UK) analysis, the greatest benefit was observed with a quadruple therapy including angiotensin receptor–neprilysin inhibitor (ARNI) + β-blocker (BB) + mineralocorticoid receptor antagonist (MRA) + sodium–glucose cotransporter 2 inhibitors (SGLT2i), which resulted as the most cost-effective strategy (12.31 quality-adjusted life-years; net monetary benefit of £338 460; UK perspective). Findings were consistent in Sweden and USA.

Conclusion

Quadruple therapy with ARNI + BB + MRA + SGLT2i had the highest probability of being the most cost-effective strategy. Our findings might inform future health economic policies and reimbursement decisions, while also considering affordability, budget impact, and implementation feasibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeCost-Benefit AnalysisHumansCost-Effectiveness AnalysisRandomized Controlled Trials as TopicAngiotensin Receptor AntagonistsSwedenAdrenergic beta-Antagonists

Stichwörter der Autor:innen

Cost-effectivenessGuideline-directed medical therapyHeart failureNetwork meta-analysis

Substanzen

Angiotensin Receptor AntagonistsAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, 118 83 Stockholm, Sweden.
  • Department of Cardiology, University of Galway, Galway, Ireland.
  • Department of Cardiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • German Centre for Cardiovascular Research (DZHK), Partner Site North, Hamburg, Germany.
  • INSERM, INRAE, Centre for Research in Epidemiology and Statistics (CRESS), Université Paris Cité and Université Sorbonne Paris Nord, Paris, France.
  • Department of Primary Education, School of Education, University of Ioannina, Ioannina, Greece.

ORCID-Profile: Valeria Valente, Carin Corovic Cabrera, Raffaele Scorza, Raphaël Porcher, Javed Butler, Gianluigi Savarese

Förderung

  • Horizon Europe program
  • EUROPA

Zitieren

APA

Laborante, R., Bianchini, E., Beer, B. N., Valente, V., Mavridis, D., Di Bidino, R., D'Amario, D., Roes, K., Mol, P., Basile, C., Corovic Cabrera, C., Scorza, R., Porcher, R., Jhund, P. S., Butler, J., & Savarese, G. (2026). A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF. European Journal of Heart Failure. https://doi.org/10.1093/ejhf/xuag233

Vancouver

Laborante R, Bianchini E, Beer BN, Valente V, Mavridis D, Di Bidino R, et al. A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF. European Journal of Heart Failure. 2026. doi:10.1093/ejhf/xuag233

BibTeX
@article{Laborante2026,
  author = {Laborante, Renzo and Bianchini, Emiliano and Beer, Benedikt N and Valente, Valeria and Mavridis, Dimitris and Di Bidino, Rossella and D'Amario, Domenico and Roes, Kit and Mol, Peter and Basile, Christian and Corovic Cabrera, Carin and Scorza, Raffaele and Porcher, Raphaël and Jhund, Pardeep S and Butler, Javed and Savarese, Gianluigi},
  title = {A NETwork meta-analysis with COST-effectiveness evaluation of pharmacological treatments for heart failure with reduced ejection fraction: NET-COST-HFrEF},
  journal = {European Journal of Heart Failure},
  year = {2026},
  doi = {10.1093/ejhf/xuag233}
}
Kostenlos starten →